John Varga

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1629231/john-varga-publications-by-year.pdf
Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

213 papers	16,781 citations	66 h-index	126 g-index
232 ext. papers	19,655 ext. citations	6.3 avg, IF	6.59 L-index

#	Paper	IF	Citations
213	PLG nanoparticles target fibroblasts and MARCO+ monocytes to reverse multi-organ fibrosis.. *JCI Insight*, **2022**,	9.9	1
212	Pathological pulmonary vascular remodeling is induced by type V collagen in a model of scleroderma. *Pathology Research and Practice*, **2021**, 220, 153382	3.4	2
211	Adiponectin Deregulation in Systemic Autoimmune Rheumatic Diseases. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
210	New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. *Expert Opinion on Investigational Drugs*, **2021**, 30, 635-652	5.9	4
209	Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. *Arthritis Research and Therapy*, **2021**, 23, 170	5.7	4
208	Inorganic pyrophosphate is reduced in patients with systemic sclerosis. *Rheumatology*, **2021**,	3.9	3
207	Linking autoimmunity, short telomeres and lung fibrosis in SSc. *Nature Reviews Rheumatology*, **2021** , 17, 511-512	8.1	0
206	Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study. *Journal of Psychosomatic Research*, **2021**, 140, 110314	4.1	3
205	Role of RP105 and A20 in negative regulation of toll-like receptor activity in fibrosis: potential targets for therapeutic intervention. *AIMS Allergy and Immunology*, **2021**, 5, 102-126	0.5	0
204	The dynamic organelle primary cilia: emerging roles in organ fibrosis. *Current Opinion in Rheumatology*, **2021**, 33, 495-504	5.3	0
203	Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications. *Current Opinion in Rheumatology*, **2021**, 33, 463-470	5.3	2
202	Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential. *Nature Reviews Rheumatology*, **2021**, 17, 596-607	8.1	6
201	Targeting CD38-dependent NAD metabolism to mitigate multiple organ fibrosis. *IScience*, **2021**, 24, 101902	6.1	16
200	Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2020**, 40, 1239-1255	9.4	43
199	Label-free spectroscopic imaging of the skin characterizes biochemical changes associated with systemic sclerosis. *Vibrational Spectroscopy*, **2020**, 109, 103102	2.1	1
198	Epigenetic regulation of the Klotho / Miz 1 axis in cigarette-smoke extract (CSE)-induced alveolar epithelial cell (AEC) mtDNA damage and apoptosis. *FASEB Journal*, **2020**, 34, 1-1	0.9	
197	Lung Cancer Survival in Patients With Autoimmune Disease. *JAMA Network Open*, **2020**, 3, e2029917	10.4	5

196	Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. *Journal of Psychosomatic Research*, **2020**, 135, 110132	4.1	13
195	Systemic Sclerosis (Scleroderma) **2020**, 575-605		
194	Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 650-660	10.2	41
193	Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies. *Seminars in Cell and Developmental Biology*, **2020**, 101, 146-160	7.5	15
192	Adipocytic Progenitor Cells Give Rise to Pathogenic Myofibroblasts: Adipocyte-to-Mesenchymal Transition and Its Emerging Role in Fibrosis in Multiple Organs. *Current Rheumatology Reports*, **2020** , 22, 79	4.9	6
191	The NADase enzyme CD38: an emerging pharmacological target for systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis. *Current Opinion in Rheumatology*, **2020**, 32, 488-496	5.3	5
190	Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. *Journal of Psychosomatic Research*, **2020**, 139, 110262	4.1	9
189	Chemical exposure-induced systemic fibrosing disorders: Novel insights into systemic sclerosis etiology and pathogenesis. *Seminars in Arthritis and Rheumatism*, **2020**, 50, 1226-1237	5.3	3
188	Calcinosis in Systemic Sclerosis: Updates in Pathophysiology, Evaluation, and Treatment. *Current Rheumatology Reports*, **2020**, 22, 73	4.9	3
187	The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib.. *Journal of Scleroderma and Related Disorders*, **2020**, 5, 40-50	2.3	24
186	and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 552-562	11.5	23
185	Short lymphocyte, but not granulocyte, telomere length in a subset of patients with systemic sclerosis. *Annals of the Rheumatic Diseases*, **2019**, 78, 1142-1144	2.4	10
184	The Primary Cilium: Emerging Role as a Key Player in Fibrosis. *Current Rheumatology Reports*, **2019**, 21, 29	4.9	8
183	Emerging targets of disease-modifying therapy for systemic sclerosis. *Nature Reviews Rheumatology*, **2019**, 15, 208-224	8.1	64
182	Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures. *Annals of the Rheumatic Diseases*, **2019**, 78, 1371-1378	2.4	16
181	Calcinosis in scleroderma made crystal clear. *Current Opinion in Rheumatology*, **2019**, 31, 589-594	5.3	4
180	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. *Arthritis and Rheumatology*, **2019**, 71, 964-971	9.5	21
179	Scleroderma Systemic Sclerosis **2019**, 743-755.e1		2

178	Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. *Journal of Rheumatology*, **2019**, 46, 176-183	4.1	14
177	Fibronectin EDA forms the chronic fibrotic scar after contusive spinal cord injury. *Neurobiology of Disease*, **2018**, 116, 60-68	7.5	18
176	Endogenous ligands of TLR4 promote unresolving tissue fibrosis: Implications for systemic sclerosis and its targeted therapy. *Immunology Letters*, **2018**, 195, 9-17	4.1	36
175	Targeting TLRs and the inflammasome in systemic sclerosis. *Pharmacology & Therapeutics*, **2018**, 192, 163-169	13.9	21
174	Adipocyte-specific Repression of PPAR-gamma by NCoR Contributes to Scleroderma Skin Fibrosis. *Arthritis Research and Therapy*, **2018**, 20, 145	5.7	19
173	Matrix protein tenascin-C expands and reversibly blocks maturation of murine eosinophil progenitors. *Journal of Allergy and Clinical Immunology*, **2018**, 142, 695-698.e4	11.5	8
172	Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans. *Arthritis and Rheumatology*, **2018**, 70, 1654-1660	9.5	8
171	An orally-active adiponectin receptor agonist mitigates cutaneous fibrosis, inflammation and microvascular pathology in a murine model of systemic sclerosis. *Scientific Reports*, **2018**, 8, 11843	4.9	24
170	TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung. *JCI Insight*, **2018**, 3,	9.9	48
169	The non-neuronal cyclin-dependent kinase 5 is a fibrotic mediator potentially implicated in systemic sclerosis and a novel therapeutic target. *Oncotarget*, **2018**, 9, 10294-10306	3.3	5
168	The novel adipokine C1q-TNF related protein 9 (CTRP9) is elevated in systemic sclerosis-associated interstitial lung disease. *Clinical and Experimental Rheumatology*, **2018**, 36 Suppl 113, 184-185	2.2	3
167	Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis. *Frontiers in Immunology*, **2018**, 9, 2434	8.4	29
166	Diffuse cardiac fibrosis quantification in early systemic sclerosis by magnetic resonance imaging and correlation with skin fibrosis. *Journal of Scleroderma and Related Disorders*, **2018**, 3, 159-169	2.3	11
165	Systemic sclerosis in 2016: Dermal white adipose tissue implicated in SSc pathogenesis. *Nature Reviews Rheumatology*, **2017**, 13, 71-72	8.1	24
164	Toll-Like Receptor-4 Signaling Drives Persistent Fibroblast Activation and Prevents Fibrosis Resolution in Scleroderma. *Advances in Wound Care*, **2017**, 6, 356-369	4.8	35
163	Right ventricular cardiomyopathy in systemic sclerosis. *Rheumatology*, **2017**, 56, 1045-1047	3.9	3
162	Transethnic meta-analysis identifies and as susceptibility genes to systemic sclerosis. *Annals of the Rheumatic Diseases*, **2017**, 76, 1150-1158	2.4	49
161	Nrf2 exerts cell-autonomous antifibrotic effects: compromised function in systemic sclerosis and therapeutic rescue with a novel heterocyclic chalcone derivative. *Translational Research*, **2017**, 183, 71-86.e1	11	22

160	Early-Life Gut Dysbiosis: A Driver of Later-Life Fibrosis?. *Journal of Investigative Dermatology*, **2017**, 137, 2253-2255	4.3	4
159	Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease. *PLoS ONE*, **2017**, 12, e0187580	3.7	46
158	Inhibition of Catenin Signaling in the Skin Rescues Cutaneous Adipogenesis in Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial of C-82. *Journal of Investigative Dermatology*, **2017**, 137, 2473-2483	4.3	32
157	Brief Report: Association of Elevated Adipsin Levels With Pulmonary Arterial Hypertension in Systemic Sclerosis. *Arthritis and Rheumatology*, **2017**, 69, 2062-2068	9.5	15
156	Adiponectin is an endogenous anti-fibrotic mediator and therapeutic target. *Scientific Reports*, **2017** , 7, 4397	4.9	46
155	Pathophysiology of Fibrosis in Systemic Sclerosis **2017**, 261-280		3
154	Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database. *Medicine (United States)*, **2017**, 96, e8980	1.8	47
153	Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. *Journal of Scleroderma and Related Disorders*, **2017**, 2, 137-152	2.3	172
152	Etiology and Pathogenesis of Scleroderma **2017**, 1400-1423.e3		1
151	Introduction: The Etiopathogenesis of Systemic Sclerosis An Integrated Overview **2017**, 133-139		1
150	Lrp5/Catenin Signaling Controls Lung Macrophage Differentiation and Inhibits Resolution of Fibrosis. *American Journal of Respiratory Cell and Molecular Biology*, **2017**, 56, 191-201	5.7	27
149	Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS) *Clinical and Experimental Rheumatology*, **2017**, 35 Suppl 106, 75-81	2.2	31
148	Tenascin-C drives persistence of organ fibrosis. *Nature Communications*, **2016**, 7, 11703	17.4	138
147	Toll-like Receptor 9 Signaling Is Augmented in Systemic Sclerosis and Elicits Transforming Growth Factor Dependent Fibroblast Activation. *Arthritis and Rheumatology*, **2016**, 68, 1989-2002	9.5	43
146	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. *Arthritis Research and Therapy*, **2016**, 18, 20	5.7	13
145	Identification of Optimal Mouse Models of Systemic Sclerosis by Interspecies Comparative Genomics. *Arthritis and Rheumatology*, **2016**, 68, 2003-15	9.5	25
144	Adiponectin inhibits Wnt co-receptor, Lrp6, phosphorylation and catenin signaling. *Biochemical and Biophysical Research Communications*, **2016**, 470, 606-612	3.4	11
143	Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study. *Seminars in Arthritis and Rheumatism*, **2016**, 46, 109-14	5.3	46

142	The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis. *Rheumatology*, **2016**, 55, 911-7	3.9	20
141	Recent Developments in the Classification, Evaluation, Pathophysiology, and Management of Scleroderma Renal Crisis. *Current Rheumatology Reports*, **2016**, 18, 5	4.9	15
140	SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis. *Oncotarget*, **2016**, 7, 69321-69336	3.3	66
139	Mutation in LEMD3 (Man1) Associated with Osteopoikilosis and Late-Onset Generalized Morphea: A New Buschke-Ollendorf Syndrome Variant. *Case Reports in Dermatological Medicine*, **2016**, 2016, 2483041	0.8	4
138	A20 suppresses canonical Smad-dependent fibroblast activation: novel function for an endogenous inflammatory modulator. *Arthritis Research and Therapy*, **2016**, 18, 216	5.7	18
137	Animal models of scleroderma: recent progress. *Current Opinion in Rheumatology*, **2016**, 28, 561-70	5.3	29
136	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. *Lancet Respiratory Medicine,the*, **2016**, 4, 708-719	35.1	487
135	The Histone Deacetylase Sirtuin 1 Is Reduced in Systemic Sclerosis and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor Signaling. *Arthritis and Rheumatology*, **2015**, 67, 1323-34	9.5	61
134	Longitudinal evaluation of PROMIS-29 and FACIT-dyspnea short forms in systemic sclerosis. *Journal of Rheumatology*, **2015**, 42, 64-72	4.1	31
133	Antinuclear antibody-negative systemic sclerosis. *Seminars in Arthritis and Rheumatism*, **2015**, 44, 680-6	5.3	43
132	A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR- gene and systemic sclerosis. *Arthritis Research and Therapy*, **2015**, 17, 128	5.7	21
131	Systemic sclerosis. *Nature Reviews Disease Primers*, **2015**, 1, 15002	51.1	351
130	Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures. *Arthritis Research and Therapy*, **2015**, 17, 194	5.7	30
129	Serum amyloid A is a marker for pulmonary involvement in systemic sclerosis. *PLoS ONE*, **2015**, 10, e0110820	3.7	27
128	Experimentally-derived fibroblast gene signatures identify molecular pathways associated with distinct subsets of systemic sclerosis patients in three independent cohorts. *PLoS ONE*, **2015**, 10, e0114017	3.7	42
127	Early stage lung cancer detection in systemic sclerosis does not portend survival benefit: a cross sectional study. *PLoS ONE*, **2015**, 10, e0117829	3.7	10
126	Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors. *Arthritis and Rheumatology*, **2015**, 67, 1062-73	9.5	195
125	Emerging roles of innate immune signaling and toll-like receptors in fibrosis and systemic sclerosis. *Current Rheumatology Reports*, **2015**, 17, 474	4.9	51

124	Etiology and pathogenesis of systemic sclerosis **2015**, 1177-1189		2
123	Connective tissue diseases: systemic sclerosis: beyond limited and diffuse subsets?. *Nature Reviews Rheumatology*, **2014**, 10, 200-2	8.1	25
122	Wnt coreceptor Lrp5 is a driver of idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 190, 185-95	10.2	80
121	Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?. *Arthritis and Rheumatology*, **2014**, 66, 1967-78	9.5	120
120	A synthetic PPAR-□agonist triterpenoid ameliorates experimental fibrosis: PPAR-□independent suppression of fibrotic responses. *Annals of the Rheumatic Diseases*, **2014**, 73, 446-54	2.4	54
119	Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. *American Journal of Human Genetics*, **2014**, 94, 47-61	11	151
118	Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction. *Nature Communications*, **2014**, 5, 3485	17.4	180
117	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. *Journal of Clinical Epidemiology*, **2014**, 67, 706-14	5.7	40
116	Emerging cellular and molecular targets in fibrosis: implications for scleroderma pathogenesis and targeted therapy. *Current Opinion in Rheumatology*, **2014**, 26, 607-14	5.3	34
115	FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling. *Science Translational Medicine*, **2014**, 6, 232ra50	17.5	154
114	Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. *Seminars in Arthritis and Rheumatism*, **2014**, 44, 55-62	5.3	56
113	Eosinophilia-Myalgia Syndrome, Eosinophilic Fasciitis, and Related Fasciitis Disorders **2014**, 1561-1573		
112	Early growth response 3 (Egr-3) is induced by transforming growth factor-□and regulates fibrogenic responses. *American Journal of Pathology*, **2013**, 183, 1197-1208	5.8	38
111	2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. *Arthritis and Rheumatism*, **2013**, 65, 2737-47		1636
110	Egr-1: new conductor for the tissue repair orchestra directs harmony (regeneration) or cacophony (fibrosis). *Journal of Pathology*, **2013**, 229, 286-97	9.4	97
109	Toll-like receptor 4 signaling augments transforming growth factor-□responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. *American Journal of Pathology*, **2013**, 182, 192-205	5.8	184
108	Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis. *Annals of the Rheumatic Diseases*, **2013**, 72, 1255-8	2.4	92
107	p300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-□epigenetic feed-forward amplification of fibrosis. *Journal of Investigative Dermatology*, **2013**, 133, 1302-10	4.3	72

106	A synthetic TLR3 ligand mitigates profibrotic fibroblast responses by inducing autocrine IFN signaling. *Journal of Immunology*, **2013**, 191, 2956-66	5.3	32
105	Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development. *Expert Review of Clinical Immunology*, **2013**, 9, 1077-90	5.1	30
104	Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. *Journal of Investigative Dermatology*, **2013**, 133, 1979-89	4.3	102
103	The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. *PLoS ONE*, **2013**, 8, e70621	3.7	113
102	Scleroderma-systemic sclerosis **2013**, 656-666		
101	Etiology and Pathogenesis of Scleroderma **2013**, 1343-1365		1
100	Fibrosis in systemic sclerosis: common and unique pathobiology. *Fibrogenesis and Tissue Repair*, **2012**, 5, S18		26
99	Proteasomal inhibition after injury prevents fibrosis by modulating TGF-(1) signalling. *Thorax*, **2012**, 67, 139-46	7.3	58
98	Systemic Sclerosis (Scleroderma) **2012**, 1705-1713		2
97	Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. *American Journal of Pathology*, **2012**, 180, 1340-55	5.8	878
96	Mechanism of Fibrosis **2012**, 255-265		1
95	The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy. *Arthritis Research and Therapy*, **2012**, 14, R229	5.7	70
94	Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker?. *Arthritis Research and Therapy*, **2012**, 14, R102	5.7	68
93	Regulation of Matrix Remodeling by Peroxisome Proliferator-Activated Receptor-A Novel Link Between Metabolism and Fibrogenesis. *Open Rheumatology Journal*, **2012**, 6, 103-15	0.2	35
92	Wnt/catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. *Arthritis and Rheumatism*, **2012**, 64, 2734-45		160
91	Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF- signaling. *Journal of Immunology*, **2012**, 189, 2635-44	5.3	72
90	The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. *Chest*, **2012**, 142, 1584-1588	5.3	53
89	Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis. *Clinical and Experimental Rheumatology*, **2012**, 30, S30-7	2.2	42

88	Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro. *Clinical and Experimental Rheumatology*, **2012**, 30, S86-96	2.2	10
87	Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. *Nature Reviews Rheumatology*, **2011**, 8, 42-54	8.1	240
86	The early growth response gene Egr2 (Alias Krox20) is a novel transcriptional target of transforming growth factor-that is up-regulated in systemic sclerosis and mediates profibrotic responses. *American Journal of Pathology*, **2011**, 178, 2077-90	5.8	62
85	Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy. *Matrix Biology*, **2011**, 30, 235-42	11.4	76
84	Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. *Autoimmunity Reviews*, **2011**, 10, 267-75	13.6	137
83	B-cell-targeted therapy for the fibrotic complications of systemic sclerosis. *Current Rheumatology Reports*, **2011**, 13, 1-3	4.9	1
82	Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma?. *Arthritis and Rheumatism*, **2011**, 63, 1707-17		156
81	Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. *Arthritis and Rheumatism*, **2011**, 63, 3633-9		48
80	Nuclear catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. *American Journal of Respiratory Cell and Molecular Biology*, **2011**, 45, 915-22	5.7	119
79	Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. *PLoS Genetics*, **2011**, 7, e1002178	6	164
78	Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis. *PLoS ONE* , **2011**, 6, e23082	3.7	30
77	Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. *Nature Genetics*, **2010**, 42, 426-9	36.3	301
76	PPARdownregulation by TGFin fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. *PLoS ONE*, **2010**, 5, e13778	3.7	132
75	A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. *Journal of Investigative Dermatology*, **2010**, 130, 694-705	4.3	112
74	Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. *Arthritis Research and Therapy*, **2010**, 12, 213	5.7	95
73	Peroxisome proliferator-activated receptor innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis. *Current Opinion in Rheumatology*, **2010**, 22, 671-6	5.3	60
72	Cyclophosphamide: a novel treatment of gastric antral vascular ectasia associated with systemic sclerosis?. *Current Rheumatology Reports*, **2010**, 12, 4-7	4.9	4
71	Systemic Sclerosis **2010**, 2913-2917		

70	Transforming growth factor-beta in systemic sclerosis (scleroderma). *Frontiers in Bioscience - Scholar*, **2009**, 1, 226-35	2.4	66
69	Hypoxia-induced alveolar epithelial-mesenchymal transition requires mitochondrial ROS and hypoxia-inducible factor 1. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2009**, 297, L1120-30	5.8	156
68	Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. *FASEB Journal*, **2009**, 23, 2968-77	0.9	104
67	Tyrosine kinase inhibitors in systemic sclerosis: the case for imatinib. *Current Rheumatology Reports*, **2009**, 11, 161-3	4.9	1
66	Transforming growth factor beta as a therapeutic target in systemic sclerosis. *Nature Reviews Rheumatology*, **2009**, 5, 200-6	8.1	220
65	Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. *American Journal of Pathology*, **2009**, 174, 519-33	5.8	184
64	Essential roles for early growth response transcription factor Egr-1 in tissue fibrosis and wound healing. *American Journal of Pathology*, **2009**, 175, 1041-55	5.8	82
63	Keratinocyte growth factor expression is suppressed in early acute lung injury/acute respiratory distress syndrome by smad and c-Abl pathways. *Critical Care Medicine*, **2009**, 37, 1678-84	1.4	33
62	The transcriptional cofactor nab2 is induced by tgf-Beta and suppresses fibroblast activation: physiological roles and impaired expression in scleroderma. *PLoS ONE*, **2009**, 4, e7620	3.7	19
61	Systemic Sclerosis and the Scleroderma-Spectrum Disorders **2009**, 1311-1351		8
60	Connective tissue growth factor/CCN2-null mouse embryonic fibroblasts retain intact transforming growth factor-beta responsiveness. *Experimental Cell Research*, **2008**, 314, 1094-104	4.2	32
59	Fibrosis in systemic sclerosis. *Rheumatic Disease Clinics of North America*, **2008**, 34, 115-43; vii	2.4	56
58	Constitutive Smad signaling and Smad-dependent collagen gene expression in mouse embryonic fibroblasts lacking peroxisome proliferator-activated receptor-gamma. *Biochemical and Biophysical Research Communications*, **2008**, 374, 231-6	3.4	34
57	Smad-independent transforming growth factor-beta regulation of early growth response-1 and sustained expression in fibrosis: implications for scleroderma. *American Journal of Pathology*, **2008**, 173, 1085-99	5.8	74
56	Antitransforming growth factor-beta therapy in fibrosis: recent progress and implications for systemic sclerosis. *Current Opinion in Rheumatology*, **2008**, 20, 720-8	5.3	74
55	In perspective: murine models of scleroderma. *Current Rheumatology Reports*, **2008**, 10, 173-82	4.9	22
54	Systemic sclerosis **2008**, 813-823		
53	Systemic sclerosis: an update. *Bulletin of the NYU Hospital for Joint Diseases*, **2008**, 66, 198-202		45

52	The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. *Journal of Cellular Physiology*, **2007**, 213, 663-71	7	142
51	Novel paradigm for treating vasculopathy in systemic sclerosis: vascular progenitor cells and statins. *Current Rheumatology Reports*, **2007**, 9, 1-3	4.9	1
50	MAP-kinase activity necessary for TGFbeta1-stimulated mesangial cell type I collagen expression requires adhesion-dependent phosphorylation of FAK tyrosine 397. *Journal of Cell Science*, **2007**, 120, 4230-40	5.3	61
49	Obliterative vasculopathy in systemic sclerosis: endothelial precursor cells as novel targets for therapy. *Expert Review of Clinical Immunology*, **2007**, 3, 11-5	5.1	2
48	Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. *American Journal of Respiratory and Critical Care Medicine*, **2007**, 176, 1026-34	10.2	343
47	Systemic sclerosis: a prototypic multisystem fibrotic disorder. *Journal of Clinical Investigation*, **2007**, 117, 557-67	15.9	782
46	Molecular pathways as novel therapeutic targets in systemic sclerosis. *Current Opinion in Rheumatology*, **2007**, 19, 568-73	5.3	28
45	Trichostatin A blocks TGF-beta-induced collagen gene expression in skin fibroblasts: involvement of Sp1. *Biochemical and Biophysical Research Communications*, **2007**, 354, 420-6	3.4	82
44	Inhibition of collagen gene expression by interferon-gamma: novel role of the CCAAT/enhancer binding protein beta (C/EBPbeta). *Journal of Cellular Physiology*, **2006**, 207, 251-60	7	32
43	Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet. *Pathobiology*, **2006**, 73, 224-37	3.6	58
42	Cyclophosphamide versus placebo in scleroderma lung disease. *New England Journal of Medicine*, **2006**, 354, 2655-66	59.2	1125
41	The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. *Journal of Biological Chemistry*, **2006**, 281, 21183-21197	5.4	130
40	Diminished induction of skin fibrosis in mice with MCP-1 deficiency. *Journal of Investigative Dermatology*, **2006**, 126, 1900-8	4.3	92
39	Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. *Journal of Investigative Dermatology*, **2006**, 126, 1733-44	4.3	72
38	Scleroderma: from cell and molecular mechanisms to disease models. *Trends in Immunology*, **2005**, 26, 587-95	14.4	223
37	Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor beta. *Arthritis and Rheumatism*, **2005**, 52, 1248-58		75
36	Animal models of scleroderma. *Methods in Molecular Medicine*, **2004**, 102, 377-93		19
35	The tumor suppressor p53 abrogates Smad-dependent collagen gene induction in mesenchymal cells. *Journal of Biological Chemistry*, **2004**, 279, 47455-63	5.4	52

34	Antifibrotic therapy in scleroderma: extracellular or intracellular targeting of activated fibroblasts?. *Current Rheumatology Reports*, **2004**, 6, 164-70	4.9	20
33	Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. *Arthritis and Rheumatism*, **2004**, 50, 1305-18		175
32	Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts. *Arthritis and Rheumatism*, **2004**, 50, 4008-21		96
31	Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management. *Treatments in Respiratory Medicine*, **2004**, 3, 339-52		39
30	Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. *American Journal of Pathology*, **2004**, 165, 203-17	5.8	195
29	Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. *Arthritis and Rheumatism*, **2003**, 48, 1964-78		154
28	Sustained activation of fibroblast transforming growth factor-beta/Smad signaling in a murine model of scleroderma. *Journal of Investigative Dermatology*, **2003**, 121, 41-50	4.3	97
27	Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis. *Arthritis and Rheumatism*, **2002**, 46, 1703-13		111
26	Methotrexate shows marginal clinical efficiency in early scleroderma. *Current Rheumatology Reports*, **2002**, 4, 97-8	4.9	1
25	Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. *Journal of Biological Chemistry*, **2002**, 277, 7726-35	5.4	133
24	Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. *Arthritis and Rheumatism*, **2001**, 44, 376-83		67
23	Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. *Journal of Biological Chemistry*, **2001**, 276, 38502-10	5.4	186
22	Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators. *Journal of Biological Chemistry*, **2001**, 276, 11041-8	5.4	190
21	Interaction of smad3 with a proximal smad-binding element of the human alpha2(I) procollagen gene promoter required for transcriptional activation by TGF-beta. *Journal of Cellular Physiology*, **2000**, 183, 381-92	7	158
20	Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP transcriptional coactivators. *Oncogene*, **2000**, 19, 3546-55	9.2	188
19	Modulation of endogenous Smad expression in normal skin fibroblasts by transforming growth factor-beta. *Experimental Cell Research*, **2000**, 258, 374-83	4.2	93
18	Progress in systemic sclerosis: novel therapeutic paradigms. *Current Rheumatology Reports*, **2000**, 2, 481-89	4	1
17	Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3. *Journal of Investigative Dermatology*, **1999**, 112, 49-57	4.3	321

16	Clinical trials for the treatment of systemic sclerosis/scleroderma. *Current Rheumatology Reports*, **1999**, 1, 13-4	4.9	
15	Negative modulation of alpha1(I) procollagen gene expression in human skin fibroblasts: transcriptional inhibition by interferon-gamma. *Journal of Cellular Physiology*, **1999**, 179, 97-108	7	50
14	Negative modulation of α1(I) procollagen gene expression in human skin fibroblasts: Transcriptional inhibition by interferon-γ **1999**, 179, 97		2
13	Identification of elements in the promoter region of the alpha1(I) procollagen gene involved in its up-regulated expression in systemic sclerosis. *Arthritis and Rheumatism*, **1998**, 41, 2048-58		56
12	Modulation of cellular tryptophan metabolism in human fibroblasts by transforming growth factor-beta: selective inhibition of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA synthetase gene expression. *Journal of Cellular Physiology*, **1998**, 177, 174-86	7	69
11	Modulation of human alpha1(I) procollagen gene activity by interaction with Sp1 and Sp3 transcription factors in vitro. *Gene*, **1998**, 215, 101-10	3.8	70
10	Identification of elements in the promoter region of the α1(I) procollagen gene involved in its up-regulated expression in systemic sclerosis **1998**, 41, 2048		1
9	Gastric antral vascular ectasia (watermelon stomach) in patients with systemic sclerosis. *Arthritis and Rheumatism*, **1996**, 39, 341-6		86
8	Inhibition of type I collagen mRNA expression independent of tryptophan depletion in interferon-gamma-treated human dermal fibroblasts. *Journal of Investigative Dermatology*, **1995**, 105, 388-93	4.3	18
7	Regulation of connective tissue synthesis in systemic sclerosis. *International Reviews of Immunology* , **1995**, 12, 187-99	4.6	51
6	Elevated levels of eosinophil major basic protein in the sera of patients with systemic sclerosis. *Arthritis and Rheumatism*, **1995**, 38, 939-45		21
5	Myopathy with mitochondrial alterations in patients with primary biliary cirrhosis and antimitochondrial antibodies. *Arthritis and Rheumatism*, **1993**, 36, 1468-75		36
4	The cause and pathogenesis of the eosinophilia-myalgia syndrome. *Annals of Internal Medicine*, **1992**, 116, 140-7	8	57
3	Eosinophilia-myalgia syndrome. *International Journal of Dermatology*, **1992**, 31, 223-8	1.7	7
2	Autoantibodies to nuclear lamin C in the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. *Arthritis and Rheumatism*, **1992**, 35, 106-9		14
1	Elevated expression of the genes for transforming growth factor-beta 1 and type VI collagen in diffuse fasciitis associated with the eosinophilia-myalgia syndrome. *Journal of Investigative Dermatology*, **1991**, 96, 20-5	4.3	37